RxDoctor Payments Data

David Lyter, MD

Internal Medicine · Tampa, FLNPI 1659320158

Payments from drug & device makers

$1,690in general payments, 2019–2025

Across 78 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$846
  • Viiv Healthcare Company$328
  • Novo Nordisk$142
  • Sanofi-aventis U.S. LLC$118
  • Bayer$115
  • Pfizer$76
  • plus $66 from 1 others

What the payments were for

  • Food & beverage$1,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,690 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$11,288
Medicare patients
45
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala48$193,052
DovatoDolutegravir Sodium/Lamivudine42$147,236
DescovyEmtricitabine/Tenofov Alafenam37$82,532
TivicayDolutegravir Sodium20$45,053
Maraviroc21$39,056
DelstrigoDoravirine/Lamivu/Tenofov Diso13$31,988
Darunavir13$20,602
MounjaroTirzepatide13$15,150
OzempicSemaglutide17$14,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,361
Levocarnitine15$1,804
Testosterone Cypionate32$1,762
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)13$994
Estradiol43$764
ValacyclovirValacyclovir Hcl29$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$846$275,58485 claims
Viiv Healthcare CompanyDovato, Tivicay$328$192,28962 claims
Novo NordiskOzempic$142$14,76017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →